Search Results - "Bagel, J"

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS) by Paller, A.S., Seyger, M.M.B., Alejandro Magariños, G., Bagel, J., Pinter, A., Cather, J., Keller, S., Rodriguez Capriles, C., Gontijo Lima, R., Gallo, G., Little, C.A., Edson‐Heredia, E., Li, L., Xu, W., Papp, K.

“…Summary Background Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited. Objectives To evaluate the…”
Get full text

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials by Silverberg, J.I., Simpson, E.L., Ardeleanu, M., Thaçi, D., Barbarot, S., Bagel, J., Chen, Z., Eckert, L., Chao, J., Korotzer, A., Rizova, E., Rossi, A.B., Lu, Y., Graham, N.M.H., Hultsch, T., Pirozzi, G., Akinlade, B.

“…Summary Background In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in…”
Get full text

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY) by Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.

“…Background Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY…”
Get full text

IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis by Paller, A.S., Tan, J.K.L., Bagel, J., Rossi, A.B., Shumel, B., Zhang, H., Abramova, A.

“…Summary Background Accurate assessment of atopic dermatitis (AD) severity is critical when initiating and monitoring therapy. Use of existing research tools…”
Get full text

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials by Blauvelt, A., Rosmarin, D., Bieber, T., Simpson, E.L., Bagel, J., Worm, M., Deleuran, M., Katoh, N., Kawashima, M., Shumel, B., Chen, Z., Rossi, A.B., Hultsch, T., Ardeleanu, M.

Get full text

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study by Van Voorhees, A.S., Stein Gold, L., Lebwohl, M., Strober, B., Sofen, H., Papp, K., Bagel, J., Zhang, Z., Paris, M., Wang, Y.

Get full text

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis by Reich, K., Mrowietz, U., Menter, A., Griffiths, C.E.M., Bagel, J., Strober, B., Nunez Gomez, N., Shi, R., Guerette, B., Lebwohl, M.

“…Background Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)‐75 is emerging as an important…”
Get full text

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A) by Callis Duffin, K., Bagel, J., Bukhalo, M., Mercado Clement, I.J., Choi, S.L., Zhao, F., Gill, A., Pangallo, B., Shuler, C., Mallbris, L., Jackson, K.

“…Background The efficacy of ixekizumab, an anti‐interleukin‐17A (anti‐IL‐17A) monoclonal IgG4 antibody, was demonstrated in moderate‐to‐severe psoriasis…”
Get full text

Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease by Bradbury, Allison, Bagel, Jessica, Sampson, Maureen, Farhat, Nicole, Ding, Wenge, Swain, Gary, Prociuk, Maria, O'Donnell, Patricia, Drobatz, Kenneth, Gurda, Brittney, Wassif, Christopher, Remaley, Alan, Porter, Forbes, Vite, Charles

“…Niemann-Pick type C (NPC) 1 disease is a rare, inherited, neurodegenerative disease. Clear evidence of the therapeutic efficacy of…”
Get more information

The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry by Merola, J.F., Perez Chada, L.M., Siegel, M., Bagel, J., Evans, C., Lockshin, B., Mason, M., Guo, N., McLean, R.R., Greenberg, J.D., Van Voorhees, A.S.

“…Introduction The National Psoriasis Foundation (NPF) published treat‐to‐target guidelines for psoriasis, yet their applicability in clinical practice remains…”
Get full text

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis by Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.

“…Summary Psoriasis is a skin disease that causes red, scaly and itchy patches of skin all over the body. It affects about 125 million people worldwide. As well…”
Get full text

Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain by Swain, G P, Prociuk, M, Bagel, J H, O'Donnell, P, Berger, K, Drobatz, K, Gurda, B L, Haskins, M E, Sands, M S, Vite, C H

“…Canine models have many advantages for evaluating therapy of human central nervous system (CNS) diseases. In contrast to nonhuman primate models, naturally…”
Get full text

Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab by Bagel, J., Tyring, S., Rice, K.C., Collier, D.H., Kricorian, G., Chung, J., Iles, J., Stolshek, B.S., Kaliyaperumal, A., Papp, K.A.

“…Summary Background Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy. Objectives To evaluate…”
Get full text

Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept by Tyring, S., Bagel, J., Lynde, C., Klekotka, P., Thompson, E.H.Z., Gandra, S.R., Shi, Y., Kricorian, G.

Get full text

Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy by Kimball, A.B., Alavian, C., Alora-Palli, M., Bagel, J.

Get full text

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究 by Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.

“…Summary 银屑病是一种皮肤病,会导致全身皮肤出现红色、鳞屑和瘙痒的斑块。 它影响着全球约 1.25 亿人。除了导致生活质量下降外,更广泛的银屑病往往会影响内在健康。过去几年开发的新药经常可以帮助银屑病患者实现完全清除皮损,并改善整体健康状况。 其中两种药物是 ixekizumab (IXE) 和…”
Get full text

Administration of DAB389IL-2 to patients with recalcitrant psoriasis : A double-blind, phase II multicenter trial by BAGEL, J, GARLAND, W. T, BRENEMAN, D, HOLICK, M, LITTLEJOHN, T. W, CROSBY, D, FAUST, H, FIVENSON, D, NICHOLS, J

“…Current therapies for recalcitrant psoriasis focus on immunoregulation and targeting of activated T-lymphocytes rather than keratinocytes. Previous studies…”
Get full text

Bimekizumab versus Adalimumab in Plaque Psoriasis by Warren, Richard B, Blauvelt, Andrew, Bagel, Jerry, Papp, Kim A, Yamauchi, Paul, Armstrong, April, Langley, Richard G, Vanvoorden, Veerle, De Cuyper, Dirk, Cioffi, Christopher, Peterson, Luke, Cross, Nancy, Reich, Kristian

“…The interleukin-17A and interleukin-17F monoclonal antibody bimekizumab led to a higher incidence of clearance of psoriasis lesions than the anti-TNF drug…”
Get full text

99 Dupilumab treatment normalizes intraepidermal nerve fiber density in patients with moderate-to-severe atopic dermatitis and improves patient-reported outcomes by Ständer, S., Agelopoulos, K., Nattkemper, L., Bagel, J., Praestgaard, A., Bologna, G., Mack, M., Zahn, J., Zhang, A., Yosipovitch, G.

Get full text

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed by Kimmel, Grace, Chima, Margot, Kim, Hee Jin, Bares, Jennifer, Yao, Christopher J., Singer, Giselle, Kim, Soo Jung, Bagel, Jerry, Lebwohl, Mark

Get full text